Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 161,025
  • Shares Outstanding, K 125,801
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,090 K
  • EBIT $ -30 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.18

Options Overview Details

View History
  • Implied Volatility 122.02% ( +6.79%)
  • Historical Volatility 57.32%
  • IV Percentile 50%
  • IV Rank 37.20%
  • IV High 273.36% on 04/05/24
  • IV Low 32.38% on 11/30/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 206
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 17,683
  • Open Int (30-Day) 16,354

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1900 +0.84%
on 11/20/24
1.6600 -27.71%
on 11/11/24
-0.2500 (-17.24%)
since 10/18/24
3-Month
1.1900 +0.84%
on 11/20/24
1.6600 -27.71%
on 11/11/24
-0.1400 (-10.45%)
since 08/20/24
52-Week
0.7000 +71.43%
on 12/13/23
2.3100 -48.05%
on 04/05/24
+0.4600 (+62.16%)
since 11/20/23

Most Recent Stories

More News
Atossa Therapeutics Announces Five Abstracts Accepted for Presentation at SABCS 2024 Featuring (Z)-Endoxifen Data in Breast Cancer Research

Atossa Therapeutics announced five accepted abstracts on (Z)-endoxifen for the San Antonio Breast Cancer Symposium in December 2024.Quiver AI SummaryAtossa Therapeutics, a clinical-stage biopharmaceutical...

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

ATOS : 1.2000 (-6.25%)
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

ATOS : 1.2000 (-6.25%)
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

/CNW/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However, this...

ONCY : 0.9985 (-5.80%)
HOLX : 78.04 (-0.67%)
KZIA : 5.61 (-1.75%)
ATOS : 1.2000 (-6.25%)
NVS : 103.09 (-0.17%)
ONC.TO : 1.40 (-5.41%)
KZA.AX : 0.080 (+9.59%)
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

ATOS : 1.2000 (-6.25%)
2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

ATOS : 1.2000 (-6.25%)
OCGN : 0.9185 (+5.14%)
$SPX : 5,917.11 (unch)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 1.3133
2nd Resistance Point 1.2867
1st Resistance Point 1.2433
Last Price 1.2000
1st Support Level 1.1733
2nd Support Level 1.1467
3rd Support Level 1.1033

See More

52-Week High 2.3100
Fibonacci 61.8% 1.6950
Fibonacci 50% 1.5050
Fibonacci 38.2% 1.3150
Last Price 1.2000
52-Week Low 0.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar